1. CD4 cell eligibility thresholds: an analysis of the time to antiretroviral treatment in HIV-1 seroconverters.
- Author
-
Minga AK, Lewden C, Gabillard D, Bomisso GI, Toni TD, Emième AA, Yapo V, Inwoley A, Salamon R, and Anglaret X
- Subjects
- Adult, Drug Therapy, Combination, HIV Seropositivity diagnosis, Humans, Male, Anti-Retroviral Agents administration & dosage, CD4 Lymphocyte Count, HIV Infections drug therapy, HIV Seropositivity drug therapy, HIV-1
- Abstract
Background: WHO recommends initiating combination antiretroviral treatment at the minimal CD4 cell threshold of 350 cells/μl. In sub-Saharan Africa, the time for a recently infected patient to reach this threshold is unclear., Method: We estimated the probability of reaching different CD4 cell thresholds over time in the ANRS 1220 cohort of HIV-1 seroconverters in Côte d'Ivoire. CD4 cell slopes were estimated using a mixed linear model. Probabilities of crossing the 350 and 500 cells/μl CD4 cell thresholds were estimated by the Kaplan-Meier method., Results: Between 1997 and 2009, 304 recent seroconverters have been enrolled in the Primo-CI cohort (62% men, median baseline age 29 years and median time since the estimated date of seroconversion 9 months). The probability of having a first CD4 cell count below 500 cells/μl was 0.57, 0.72, 0.79 and 0.84 at study entry, 2, 4 and 6 years, respectively. For a first CD4 cell count below 350 cells/μl, these figures were 0.29, 0.40, 0.55 and 0.67. The time for 75% of patients to reach the threshold was 3.0 years for 500 cells/μl and 7.0 years for 350 cells/μl.
- Published
- 2011
- Full Text
- View/download PDF